Buprenorphine-naloxone treatment in opioid dependence and risk of liver enzyme elevation: results from a 12-month observational study.
about
Opioid Drugs in Patients With Liver Disease: A Systematic ReviewNew developments in the management of opioid dependence: focus on sublingual buprenorphine-naloxone.Hepatic Safety of Buprenorphine in HIV-Infected and Uninfected Patients With Opioid Use Disorder: The Role of HCV-Infection.Treatment of opioid dependence with buprenorphine: current update.
P2860
Buprenorphine-naloxone treatment in opioid dependence and risk of liver enzyme elevation: results from a 12-month observational study.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh-hant
name
Buprenorphine-naloxone treatme ...... 12-month observational study.
@en
Buprenorphine-naloxone treatme ...... 12-month observational study.
@nl
type
label
Buprenorphine-naloxone treatme ...... 12-month observational study.
@en
Buprenorphine-naloxone treatme ...... 12-month observational study.
@nl
prefLabel
Buprenorphine-naloxone treatme ...... 12-month observational study.
@en
Buprenorphine-naloxone treatme ...... 12-month observational study.
@nl
P2093
P2860
P1476
Buprenorphine-naloxone treatme ...... a 12-month observational study
@en
P2093
Markus Backmund
Michael Soyka
Peggy Schmidt
P2860
P304
P356
10.1111/J.1521-0391.2014.12131.X
P50
P577
2014-09-22T00:00:00Z